Assembly Biosciences raises $115M gross in underwritten equity offering; underwriters exercise option in full

ASSEMBLY BIOSCIENCES, INC.

Closed offering of 3,924,624 common shares at $26.50 and pre-funded warrants for 415,000 shares at $26.499.
Net proceeds of approximately $107.4M after underwriting discounts and estimated expenses.
Investors include Gilead Sciences, Commodore Capital, Farallon Capital, and others.
Proceeds to fund clinical development of pipeline candidates and for general corporate purposes.
Underwriters' 30-day option for 566,040 additional shares exercised in full on May 22.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ASSEMBLY BIOSCIENCES, INC. entered into Underwriting Agreement with Guggenheim Securities, LLC and UBS Securities LLC, as representatives of the several underwriters valued at approximately $107.4 million (effective 2026-05-21).

Action: entry
Agreement: underwriting
Counterparty: Guggenheim Securities, LLC and UBS Securities LLC, as representatives of the several underwriters
Value: approximately $107.4 million
Effective: 2026-05-21

Exact text from the filing

On May 21, 2026, Assembly Biosciences, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Guggenheim Securities, LLC ("Guggenheim Securities") and UBS Securities LLC, as representatives of the several underwriters listed in Schedule A thereto (the "Underwriters"), in connection with the issuance and sale, in an underwritten, registered offering (the "Offering"), of: (1) 3,358,602 shares (the "Offering Shares") of the Company's common stock, par value $0.001 per share (the " Common Stock "), at an offering price of $26.50 per share; and (2) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 415,000 shares of Common Stock (the "Pre-Funded Warrant Shares"), at an offering price of $26.499 per Pre-Funded Warrant.

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

ASSEMBLY BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-239277

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.